Abstract
Omalizumab (Xolair), which was originally licensed for IgE‐mediated asthma, is now indicated as adjunctive therapy for chronic spontaneous urticaria. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events, and Dr Clive Grattan discusses its place in therapy.
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for freeCite
CITATION STYLE
APA
Chaplin, S., & Grattan, C. (2014). Omalizumab: now licensed as adjunct for urticaria. Prescriber, 25(17), 37–38. https://doi.org/10.1002/psb.1239
Readers' Seniority
Readers' Discipline
